Modified Factor VII Polypeptides with Heterologous Gla Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemophilia A and B, particularly those using recombinant Factor VIIa, require multiple doses to manage acute bleeding episodes and have limitations due to antibody development and efficacy issues, necessitating more effective therapeutic variants of Factor VII polypeptides.
Innovation Solution
Development of modified Factor VII polypeptides with enhanced properties, including increased phospholipid affinity, resistance to inhibitors like antithrombin-III and tissue factor pathway inhibitor, improved pharmacokinetics, and altered conformation to enhance coagulant activity, stability, and reduced immunogenicity, utilizing heterologous Gla domains and specific amino acid modifications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If recombinant FVIIa is used to manage acute bleeding episodes, then clot formation is promoted, but multiple doses are required over extended time periods
Solution Approach 1:
The patent modifies the FVIIa protein sequence through specific amino acid substitutions (e.g., at positions 196, 237, 341) to alter its pharmacokinetic properties and half-life, enabling prolonged therapeutic effect with reduced dosing frequency while maintaining clot formation efficiency
2Reliability
If recombinant FVIIa is administered to hemophilia patients, then bleeding episodes are managed, but antibody development reduces treatment efficacy
Solution Approach 1:
The patent introduces heterologous Gla domains from different species (e.g., mouse, rat, bovine) to create localized structural differences in the FVIIa molecule that reduce immunogenicity while preserving coagulant function, thereby reducing antibody formation against the therapeutic protein
3Reliability
If FVIIa therapy is used to stop bleeding, then coagulation is enhanced, but the complexity of dosing and monitoring increases
Solution Approach 1:
The patent modifies FVIIa to have extended half-life and improved pharmacokinetics through specific sequence changes, allowing for reduced dosing frequency and simplified monitoring protocols while maintaining reliable bleeding control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified Factor VII polypeptides demonstrate improved coagulant activity, increased stability, and reduced immunogenicity, potentially requiring fewer doses and offering better management of bleeding disorders with enhanced therapeutic efficacy.
Implementation Method 1
a heterologous Gla domain, or a sufficient portion thereof to effect phospholipid binding, whereby the modified FVII polypeptide exhibits increased phospholipid affinity or binding compared with an unmodified FVII polypeptide
Implementation Method 2
one or more further amino acid modification(s) that increases resistance to antithrombin-III (AT-III)
Implementation Method 3
increases affinity for tissue factor (TF)
Implementation Method 4
alters the conformation of the polypeptide to alter zymogenicity, increases catalytic or coagulant activity by shifting the equilibrium between highly active and less active FVIIa conformations
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor Vila and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics.